PL362350A1 - Mutanty chemokin w leczeniu stwardnienia rozsianego - Google Patents

Mutanty chemokin w leczeniu stwardnienia rozsianego

Info

Publication number
PL362350A1
PL362350A1 PL01362350A PL36235001A PL362350A1 PL 362350 A1 PL362350 A1 PL 362350A1 PL 01362350 A PL01362350 A PL 01362350A PL 36235001 A PL36235001 A PL 36235001A PL 362350 A1 PL362350 A1 PL 362350A1
Authority
PL
Poland
Prior art keywords
treatment
multiple sclerosis
chemokine mutants
chemokine
mutants
Prior art date
Application number
PL01362350A
Other languages
English (en)
Other versions
PL204231B1 (pl
Inventor
Amanda Proudfoot
Timothy N.C. Wells
Marie Kosko-Vilbois
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of PL362350A1 publication Critical patent/PL362350A1/pl
Publication of PL204231B1 publication Critical patent/PL204231B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL362350A 2000-10-04 2001-10-03 Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza PL204231B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00121665 2000-10-04

Publications (2)

Publication Number Publication Date
PL362350A1 true PL362350A1 (pl) 2004-10-18
PL204231B1 PL204231B1 (pl) 2009-12-31

Family

ID=8170011

Family Applications (1)

Application Number Title Priority Date Filing Date
PL362350A PL204231B1 (pl) 2000-10-04 2001-10-03 Zastosowanie mutanta chemokiny CC, kompozycja farmaceutyczna do leczenia stwardnienia rozsianego, skrócona i zmutowana ludzka RANTES i sposób jej wytwarzania, cząsteczka DNA i zawierający ją wektor ekspresyjny oraz komórka gospodarza

Country Status (30)

Country Link
US (1) US7402303B2 (pl)
EP (1) EP1326628B1 (pl)
JP (1) JP3908165B2 (pl)
KR (1) KR100837898B1 (pl)
CN (1) CN1285381C (pl)
AR (1) AR030854A1 (pl)
AT (1) ATE265222T1 (pl)
AU (2) AU2002215919B2 (pl)
BG (1) BG66137B1 (pl)
BR (1) BR0114407A (pl)
CA (1) CA2423616C (pl)
CZ (1) CZ303409B6 (pl)
DE (1) DE60103078T2 (pl)
DK (1) DK1326628T3 (pl)
EA (1) EA006137B1 (pl)
EE (1) EE05174B1 (pl)
ES (1) ES2217199T3 (pl)
HR (1) HRP20030215B1 (pl)
HU (1) HUP0302194A3 (pl)
IL (2) IL155178A0 (pl)
MX (1) MXPA03003008A (pl)
NO (1) NO330278B1 (pl)
PL (1) PL204231B1 (pl)
PT (1) PT1326628E (pl)
RS (1) RS50738B (pl)
SI (1) SI1326628T1 (pl)
SK (1) SK287523B6 (pl)
UA (1) UA77950C2 (pl)
WO (1) WO2002028419A2 (pl)
ZA (1) ZA200302315B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458756B1 (en) 2001-12-17 2009-01-28 Laboratoires Serono SA Chemokine mutants acting as chemokine antagonists
US7335350B2 (en) 2002-04-04 2008-02-26 Laboratoires Serono Sa Chemokines mutants having improved oral bioavailability
ATE394117T1 (de) 2002-12-23 2008-05-15 Serono Lab Verwendung von cc-chemokine ccl5/rantes mutanten zur behandlung von lebererkrankungen
JP2007533300A (ja) * 2003-10-22 2007-11-22 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 新規のｃｘｃｌ８アンタゴニスト
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
DK1439191T3 (da) * 2004-01-19 2006-08-14 Ares Trading Sa Proces til oprensning af bakterielt udtrykte proteiner
GB0412400D0 (en) * 2004-06-03 2004-07-07 Univ Newcastle Treatment of inflammatory conditions
EP2218748B1 (en) * 2005-09-03 2012-10-10 Samsung SDI Co., Ltd. Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en) 2006-07-25 2006-09-06 Univ Geneve Cytokine derivatives
ES2453592T3 (es) 2007-08-02 2014-04-08 Novimmune Sa Anticuerpos anti-RANTES y métodos de uso de los mismos
EP2539354B1 (en) * 2010-02-08 2017-04-05 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
WO2019229615A1 (en) 2018-05-28 2019-12-05 Université De Genève Methods of inhibiting cerebral inflammation
US20250186520A1 (en) * 2020-10-26 2025-06-12 City Of Hope Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
ATE308617T1 (de) 1997-12-23 2005-11-15 San Raffaele Centro Fond Rantes mutanten und deren therapeutischen anwendungen
AU2740900A (en) * 1999-01-29 2000-08-18 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists

Also Published As

Publication number Publication date
CA2423616C (en) 2010-03-16
BR0114407A (pt) 2003-07-29
SI1326628T1 (en) 2004-10-31
KR100837898B1 (ko) 2008-06-13
KR20030034238A (ko) 2003-05-01
DE60103078D1 (de) 2004-06-03
IL155178A (en) 2009-07-20
DK1326628T3 (da) 2004-08-09
AU2002215919B2 (en) 2005-11-24
SK4062003A3 (en) 2003-08-05
US7402303B2 (en) 2008-07-22
HUP0302194A3 (en) 2005-12-28
HK1062811A1 (en) 2004-11-26
MXPA03003008A (es) 2003-07-14
EA200300439A1 (ru) 2003-08-28
AU1591902A (en) 2002-04-15
CZ2003947A3 (cs) 2003-11-12
DE60103078T2 (de) 2005-04-07
ATE265222T1 (de) 2004-05-15
YU25703A (sh) 2006-05-25
HRP20030215A2 (en) 2005-02-28
ES2217199T3 (es) 2004-11-01
HRP20030215B1 (en) 2011-09-30
AR030854A1 (es) 2003-09-03
US20040101509A1 (en) 2004-05-27
HUP0302194A2 (hu) 2003-10-28
PL204231B1 (pl) 2009-12-31
NO20031525D0 (no) 2003-04-03
WO2002028419A2 (en) 2002-04-11
ZA200302315B (en) 2004-03-25
NO20031525L (no) 2003-04-03
JP3908165B2 (ja) 2007-04-25
WO2002028419A3 (en) 2002-06-13
IL155178A0 (en) 2003-11-23
SK287523B6 (sk) 2011-01-04
PT1326628E (pt) 2004-09-30
CN1285381C (zh) 2006-11-22
UA77950C2 (en) 2007-02-15
EP1326628B1 (en) 2004-04-28
NO330278B1 (no) 2011-03-21
EE05174B1 (et) 2009-06-15
CA2423616A1 (en) 2002-04-11
CN1477969A (zh) 2004-02-25
BG66137B1 (bg) 2011-07-29
EE200300139A (et) 2003-06-16
JP2004510426A (ja) 2004-04-08
EA006137B1 (ru) 2005-10-27
EP1326628A2 (en) 2003-07-16
RS50738B (sr) 2010-08-31
CZ303409B6 (cs) 2012-09-05
BG107685A (bg) 2003-11-28

Similar Documents

Publication Publication Date Title
AU4244200A (en) Multi-functional therapeutic compress and methods of using the same
SG85153A1 (en) Polishing composition and polishing process
ZA983452B (en) Substituted pyrrolopyridines useful in the treatment of inflammatory diseases.
MXPA03002813A (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias.
PL344451A1 (en) Use of cyclosporins in the treatment of inflammatory autoimmune diseases
HUP0302194A3 (en) Chemokine mutants in the treatment of multiple sclerosis
EP1222212A4 (en) MUTANTS OF IL-13
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002243363A8 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
IL152996A0 (en) Novel interferon for the treatment of multiple sclerosis
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
GB0014356D0 (en) Treatment of multiple sclerosis
GB0014580D0 (en) Appatarus and process
AU5565401A (en) Materials and methods for the treatment of depression
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
IL162507A (en) Use of ifnar2 mutants in the manufacture of medicaments
AU8609201A (en) Reduction of the electrocardiographic ot interval
AU3264202A (en) Novel human kinases and polynucleotides encoding the same
HUP0201800A2 (en) Novel calpains and their use
AU5104101A (en) Composition and use
AU2001229977A1 (en) Novel polypeptide---f-box structure protein 65 and polynucleotide encoding it
AU2998401A (en) Novel polypeptide---tbc region 32 and polynucleotide encoding it
AU5025801A (en) Novel polypeptide---a human hexose kinase 13 and polynucleotide encoding it
GB9826894D0 (en) Chemokine and uses thereof

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20131003